Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss*

Authors

  • Toshitaka Sugi,

    Corresponding author
    1. Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan
      Toshitaka Sugi MD PhD, Department of Obstetrics and Gynecology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan. Email: sugi@is.icc.u-tokai.ac.jp
    Search for more papers by this author
  • Hidehiko Matsubayashi,

    1. Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan
    Search for more papers by this author
  • Akifumi Inomo,

    1. Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan
    Search for more papers by this author
  • Lu Dan,

    1. Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan
    Search for more papers by this author
  • Tsunehisa Makino

    1. Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan
    Search for more papers by this author

  • *

    Report of the Japan Antiphospholipid Project Group

Toshitaka Sugi MD PhD, Department of Obstetrics and Gynecology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan. Email: sugi@is.icc.u-tokai.ac.jp

Abstract

Aim:  Associations have been reported between antiphospholipid antibodies (aPL), mainly anticardiolipin antibodies (aCL) and/or the lupus anticoagulant, and recurrent pregnancy losses (RPL). However, relatively few studies describing antiphosphatidylethanolamine antibodies (aPE) have been reported. We describe the prevalence of aPL to both cardiolipin and phosphatidylethanolamine in patients with RPL.

Methods:  Patients with recurrent early pregnancy losses (n = 145) and mid-to-late pregnancy loss(es) (n = 26) were screened for aPE and aCL.

Results:  In patients with recurrent early pregnancy losses, prevalence of immunoglobulin G (IgG) aPE (17.9%, P = 0.001) and immunoglobulin M (IgM) aPE (12.4%, P = 0.01) was significantly higher than in the control group. In patients with mid-to-late pregnancy loss(es), prevalence of IgM aPE (19.2%, P = 0.008) and IgG aCL (23.1%, P = 0.02) was significantly higher than in the control group.

Conclusion:  Our data suggest that aPE may be a risk factor in patients with mid-to-late pregnancy loss(es) as well as recurrent early pregnancy losses.

Ancillary